UK MHRA Aligns with INmune Bio on Ebstrocel Conditional MAA, Paving Way for 2026 Submission
INMB sits 30% above its 52-week low of $1.09.
Summary
INmune Bio received positive alignment from the UK's MHRA for its planned 2026 conditional Marketing Authorization Application (MAA) for Ebstrocel (CORDStrom™) in RDEB. The MHRA confirmed agreement on CMC, non-clinical, and clinical evidence packages, providing a clear regulatory path. This news follows an 8-K filed minutes earlier today disclosing the same positive regulatory feedback. This is a crucial step towards potential commercialization in the UK for Ebstrocel, offering a clearer path to market for one of its key drug candidates. For a small biotech company with a going concern warning, securing regulatory alignment significantly de-risks the development pathway and provides a potential revenue stream. The company plans to submit the conditional MAA in 2026.
At the time of this announcement, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.